<DOC>
	<DOCNO>NCT02934061</DOCNO>
	<brief_summary>Open label , randomize , control , multicenter study two parallel group patient</brief_summary>
	<brief_title>Study Assess Efficacy Safety Tizaspray® Versus Sirdalud® , Patients With Acute Low Back Pain</brief_title>
	<detailed_description>This phase III , open label , randomize , control , multicenter study two parallel group patient . Tizaspray® 0.5 mg ( new pharmaceutical form , liquid nasal spray solution ) , propose trial ready use treatment short term therapy painful muscle spasm acute low back pain .</detailed_description>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>1 . Age 18 65 year old 2 . Average low back pain intensity moderate severe ( ≥ 60 mm VAS ) Visit 1 3 . Positivity Schober test ( i.e . measure &lt; 5 cm ) Visit 1 4 . Acute low back pain start least 24 hour prior inclusion trial 6 week last episode acute low back pain 5 . Negative pregnancy test woman childbearing potential ( perform Visit 1 ) use acceptable mean contraception ( condom mechanical method ) previous 2 month whole duration study 6 . Signed Informed Consent 1 . History chronic low back pain 2 . Current treatment drug significant effect alpha2 receptor whether agonist ( i.e. , clonidine , methyldopa ) antagonist ( i.e. , phenothiazine , imipramine ) 3 . Current treatment muscle relaxant drug muscle relaxant property 4 . Known allergy , hypersensitivity , intolerance tizanidine paracetamol excipients use manufacture ( included patient know rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption ) 5 . Signs nasal congestion , nasal polyp , mucosal lesion nostril , postnasal drip etiology clinically significant nasal pathology may affect absorption study medication assessment safety 6 . Evidence clinically unstable disease , determine medical history , physical examination , , Investigator 's opinion , preclude entry study 7 . Spinal surgery within 1 year study entry 8 . Evidence clinical gastrointestinal malabsorption 9 . Use steroid within 3 month study entry longterm treatment steroid 10 . Use NSAID 's antiinflammatory drug 6 hour prior study inclusion 11 . Use fluvoxamine ciprofloxacin , inhibitor CYP1A2 antiarrhythmic ( amiodarone , mexiletine , propafenone ) , cimetidine , fluoroquinolones ( enoxacin , pefloxacin , norfloxacin ) , rofecoxib , oral contraceptive , ticlopidine 12 . Use hypnotic CNS depressants 13 . Blood pressure &lt; 100/70 mmHg 14 . History lumbar spinal stenosis , fibromyalgia , ankylose spondylitis 15 . Severe scoliosis 16 . More severe pain region low back 17 . Acute low back pain associated chill fever 18 . Pregnancy , breast feeding 19 . Treatment another investigational agent within last 30 day 20 . Known suspected history alcohol drug abuse base medical history , physical examination , Investigator 's clinical judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute low back pain</keyword>
</DOC>